Alector Q3 2022 net loss $46.1M, cash $758.3M, pipeline advances

Alector, Inc.

2022-Q3 EPS reported -$0.98 revenue$119,177,000

Net loss of $46.1M ($0.56 loss per share); prior-year net income $126.6M ($1.56 EPS).
Collaboration revenue $14.9M, down from $182.4M YoY due to $173.4M GSK license in 2021.
Cash, cash equivalents and investments $758.3M; runway through 2024.
Enrolling Phase 3 INFRONT-3 (latozinemab for FTD-GRN) and Phase 2 INVOKE-2 (AL002 for early AD).
Initiated Phase 1 for AL044 (MS4A target for Alzheimer’s); IND for AL009 (immuno-oncology) expected Q4 2022.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

Alector, Inc. reported the quarter ended September 30, 2022 results: revenue $14.9 million.

Period: the quarter ended September 30, 2022
Revenue: $14.9 million
Result: reported results

Exact text from the filing

research pipeline and helps drive business strategy. Third Quarter 2022 Financial Results Revenue. Collaboration revenue for the quarter ended September 30, 2022, was $14.9 million, compared to $182.4 million for the same period in 2021. The decrease of $167.6 mil

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Alector, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-22-023214

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.